Publications by authors named "John Buse"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

846

Total Likes

145

Extended Reach

249,572

Social Features

66
T
The Forces Reshaping America's Health Landscape for People With Diabetes-This Is Not About DEI, This Is About Whether People Live or DIE.
Cheryl A M Anderson, John B Buse, Steven E Kahn, Elizabeth Selvin

Diabetes Care· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three Years on at Diabetes Care: Achievements, New Initiatives, and Fresh Challenges.
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin

Diabetes Care· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
Johannes F E Mann, Nikolaus Marx, John E Deanfield, Scott S Emerson, Silvio E Inzucchi, John B Buse

Diabetes Care· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Stephen J Nicholls, Imre Pavo, Deepak L Bhatt, John B Buse, Stefano Del Prato

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of COVID-19 on Incident Diabetes in Pediatric Patients: Findings From the National COVID-19 Cohort Collaborative (N3C).
Rachel Wong, Talia Wiggen, Margaret A Hall, Steven G Johnson, Jared D Huling, John B Buse

Pediatr Diabetes· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
Ildiko Lingvay, Sara J Bergenheim, John B Buse, Paula Freitas, W Timothy Garvey

Lancet Diabetes Endocrinol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why Early, Large-scale Weight Loss Is the Future of Type 2 Diabetes Care.
Naveed Sattar, John B Buse

Diabetes Care· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel high dimensional approach to assess heterogeneous treatment effect in claims data.
Tiansheng Wang, Virginia Pate, Richard Wyss, John B Buse, Michael R Kosorok

Am J Epidemiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes.
Clement O Acheampong, John B Buse, Klara R Klein, Lawrence T Kim, Joshua Evron

BMJ Open Diabetes Res Care· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.
John B Buse, Helene Nordahl Christensen, Brian J Harty, Mark J Cziraky, Vincent J Willey

BMJ Open Diabetes Res Care· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit.
Jesica D Baran, Charles Spanbauer, Rajlaxmi Bais, Hou-Hsien Chiang, Jing H Chao, John B Buse

Diabetes Technol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups.
Tiansheng Wang, Jeanny H Wang, Alan C Kinlaw, Richard Wyss, Virginia Pate, John B Buse

Pharmacoepidemiol Drug Saf· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of Dexcom G6 Pro Continuous Glucose Monitor in the Intensive Care Setting: TIGHT ICU G6 Study.
Jagdeesh Ullal, Charles Spanbauer, Jesica D Baran, Rajlaxmi Bais, Hou-Hsien Chiang, John B Buse

Diabetes Technol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
Anthony E Peters, Maggie Nguyen, Jennifer B Green, Ewan R Pearson, John B Buse

Sci Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity.
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, David A D'Alessio

Diabetes· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity.
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, David A D'Alessio

Diabetes Care· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin.
John W Ostrominski, Vanita R Aroda, Uffe C Braae, Christian Kruse, Kabirdev Mandavya, John B Buse

Diabetes Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.
Daniel S Hsia, Naji Younes, Alokananda Ghosh, Erin J Kazemi, Heidi Krause-Steinrauf, John B Buse

Diabetes Care· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Nikolaus Marx, John E Deanfield, Johannes F E Mann, Rosario Arechavaleta, Stephen C Bain, John B Buse

Circulation· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
Vanita R Aroda, Nils B Jørgensen, Bharath Kumar, Ildiko Lingvay, Anne Sofie Laulund, John B Buse

Diabetes Care· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, John Deanfield, Scott S Emerson, John B Buse

Diabetes Care· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi, John B Buse

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis